Dr Liptrott has a background in pharmacology, immunology, and molecular cell biology. He was awarded a tenure-track fellowship (2015), within the department of Pharmacology and Therapeutics, prior to becoming Lecturer (2018) and subsequently, Reader (2021) where he leads a number of advanced therapeutics/materials immunocompatibility research projects, and programs. His research is aimed at investigating the biological interactions of conventional and nanotechnology-enabled medicines and therapeutics as well as other novel therapeutic strategies such as cellular therapies. This work encompasses the assessment of the biocompatibility, immunomodulatory potential and risk of these novel therapeutic strategies. An understanding of these, potential, interactions is vital to preclinical evaluation as well as enabling the future rational design of nanomaterials and therapies. In addition to immunological and haematological systems, Dr Liptrott's team is also investigating impacts on cellular health and metabolism that may underpin these interactions. Additionally, they are building structure-activity relationships between nanomaterial characteristics and their impact on biological systems using established, as well as novel, techniques. To date, their research has helped underpin the successful translation of solid drug nanoparticle formulations, through GMP manufacture, towards healthy volunteer bioequivalence studies. His group continues to support developers of advanced therapeutics in their efforts to reach clinical studies.
He is a member of the Executive Board, Core Expert Team (CET) and Assay Group leader (Immunotoxicity and Haematoxicity) for the European Nanomedicine Characterisation Laboratory (EUNCL). He leads the University of Liverpool's assay groups on nanoparticle biocompatibility and structure-activity relationships. He has worked, as a visiting researcher, at the National Institutes of Health (NIH) National Cancer Institute’s (NCI) Nanotechnology Characterisation Laboratory (NCL) based in Frederick, Maryland, USA. Dr Liptrott continues to receive numerous national and international invitations to speak as well as being a peer reviewer for a number of scientific journals including those with a focus on nanomedicine.
Dr Liptrott is the coordinator for the Nanotherapeutics Hub (NTH), Biocompatibility Theme Lead for the Centre of Excellence for Long-acting Therapeutics (CELT), and a platform manager for nanotherapeutics, within the Infection Innovation Consortium (iiCON)
Memberships of Professional Bodies & Leaned Societies:
2022 - present, Fellow of the Royal Society of Biology (FRSB)
2019 - present, Member of the British Toxicological society
2019 – present, Member of the British Pharmacological Society
2018 – present, Member of the American Society for Testing and Materials (ASTM, committee membership E56 – nanomedicines)
2018 – present, Fellow of the Higher Education Authority (HEA)
2013 – present, Member of the European Society for Nanomedicine
2011 – present, Executive Board member of the British Society for Nanomedicine
2004 – present, Member of the British Society for Immunology
Keywords: advanced therapies and therapeutics, liposomes, lipidic nanoparticles (LNP), Complement, Complosome, CARPA, pseudoallergy, hypersensitivity, complex medicines, extracellular vesicles, exosomes, nanoparticles, nanomedicines, nanotherapeutics, biomaterials, biocompatibility, immunology, immunotoxicology, immune engineering, intracellular drug delivery (ICD), immune response, drug disposition, human immune cells immune metabolism, microenvironment, membrane transporters, biocompatibility.